Marina-Chiara Garassino

16PUBLICATIONS
224CO-AUTHORS
Molecular targetsQuantum information, computation and communicationPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Oct 02, 2026
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

|Feb 05, 2026
Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes.

Uri Zvi, Shivam Mundhra, David Ovetsky

|Sep 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Alessio Cortellini, Valentina Santo, Leonardo Brunetti

|Jun 11, 2025
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.

Marina C Garassino, Ying Cheng, Delvys Rodriguez-Abreu

|Mar 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro

|Sep 09, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares

Pageof 3

Frequent Collaborators

5 joint publications

Luis Paz-Ares

4 joint publications

Giannis S Mountzios

4 joint publications

Enriqueta Felip

3 joint publications

Daniel S W Tan